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Abstract 
Pentameric ligand-gated ion channels (pLGICs, also known as Cys-loop receptors) are a large family of 
ion channels expressed in all Bilateria and in several groups of bacteria and archaea. They are activated 
by small-molecule neurotransmitters to mediate fast transmission at many central and peripheral 
nervous system synapses and are the target of several drugs and insecticides. Here we review recent 
advances in the field, focussing on new insights on the structure of the agonist-binding site and on 
newly discovered protein-protein interactions involving pLGICs.   
Highlights 
- Atomic basis for ligand binding and exclusion in 42 acetylcholine receptors 
- Identification of new toxins modulators and evolution of toxin resistance  
- Proposed chaperones and auxiliary subunits for pentameric ligand-gated ion channels 
- Pharmacological targeting of protein-protein interactions 
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Introduction 
In man, pentameric ligand-gated ion channels include both cation-permeable channels, such as 
nicotinic acetylcholine receptors (nAChRs) and serotonin receptors (5-HT3Rs), and anion-permeable 
channels, such as -aminobutyric acid type A (GABAARs) and glycine receptors (GlyRs).   
nAChRs mediate synaptic excitation in the periphery, at the neuromuscular junction between motor 
neurones and skeletal muscle (muscle nAChRs) and at autonomic ganglion synapses (neuronal 
nAChRs). In the mammalian central nervous system (CNS), all fast inhibitory transmission is mediated 
by pLGICs, either by one of the many subtypes of GABAARs, or by one of the (relatively few) subtypes 
of GlyRs.  Many subunits are available to form each pLGIC class, especially for GABAARs and neuronal 
nAChRs, and in the CNS many different subunit combinations are expressed in precise spatio-temporal 
patterns that change during development. Mutations in pLGICs can cause inherited human 
channelopathies, ranging from congenital myasthenias for muscle nAChRs [1] to various forms of 
epilepsy (most commonly linked to GABAAR malfunction [2]), to the specific neurological syndrome of 
startle disease in the case of GlyR mutations. These monogenic inherited channelopathies are 
relatively rare as a cause of human disease, but their phenotype underscores the physiological 
importance of pLGICs, and the location of loss-of-function mutations provides useful clues to the 
functional anatomy of these proteins. Given the physiological importance of pLGICs, it is not surprising 
that they are the target of many drugs: neuromuscular blockers and nicotine target nAChRs, propofol 
and benzodiazepines enhance the function of GABAARs and the antiemetic ondansetron blocks 5-
HT3Rs. Antiparasitic drugs, such as ivermectin, and insecticides (fipronil, neo-nicotinoids) exploit 
pharmacological differences between mammalian and invertebrate pLGICs. 
The structure of the pLGIC binding site: one heteromer and more homomers… 
A pLGIC is formed by five subunits arranged around a central ion-conducting pore. Each subunit has 
an N-terminal extracellular domain (ECD) consisting of two  sheets sandwiched together. The ECD is 
connected to the transmembrane domain (TMD), which comprises four membrane-spanning helices, 
the second of which lines the channel pore. Between the third and fourth transmembrane helices, a 
linker of variable length forms a cytoplasmic domain, with portals for ion flow and sites for interaction 
with the cytoskeleton. The binding sites for the neurotransmitter/agonist are at the interface between 
the ECDs of adjacent subunits, where the anticlockwise subunit contributes the principal (+) side with 
its three loops A, B and C [3], and the clockwise subunit the complementary (-) side, with loops D, E 
and F (in reality two  strands and one loop).  
This picture first emerged from cryo-electron microscopy (cryo-EM) data of Torpedo nAChRs [4] 
refined with high-resolution X-ray data of a soluble homologue of the nAChR ECD, the ACh binding 
protein [5]. Several crystal structures followed, both of homologous prokaryotic channels (GLIC and 
ELIC [6-8]) and of eukaryotic pLGICs: C. elegans glutamate-gated chloride channel (GluCl) [9], 3 
GABAAR [10], 5-HT3R [11] and 3 GlyR [12]. In 2015, the first application of single particle cryo-EM to 
a pLGIC, the zebrafish GlyR, broke new ground in the field of pLGIC structural studies [13**]. Cryo-EM 
will make it easier to obtain structural information for different states of the same channel type. This 
is important for pLGICs, because sequence homology across different pLGICs is fairly low. The largest 
range of structurally determined conformations is currently available for GlyR and for GLIC. Structures 
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of such different conformations provide key start and endpoints for in silico molecular dynamics 
simulations [14**]. The robustness of GLIC as a protein has allowed it to be probed in spin-
labelling/EPR spectroscopy [15-18] and with fluorescence quenching [19**]. For recent reviews that 
cover pLGIC function in greater detail see references [20-25].   
2016 has seen the publication of the first X-ray crystal structure of a heteromeric pLGIC, the human 
42 neuronal nAChR [26**], the main CNS target of the addictive action of nicotine [27;28]. This 
channel poses a particular challenge, because it assembles in two stoichiometric forms, with either 
two or three copies of the  subunit in the pentamer, a peculiarity shared by the peripheral 34 
neuronal nAChR [29]. The two forms of the 42 receptor differ in sensitivity to agonists, conductance 
and calcium permeability [30;31]. Expression can be driven towards either of the two forms by 
manipulating  transfection ratios [32], by employing fully concatenated pentameric constructs 
[33;34] or by exposing the expression system to nicotine [35].   
Morales-Perez and co-workers purified a single stoichiometric form of the 42 receptor, the one that 
contains two 4 subunits (termed 2-). This was done by monitoring the stoichiometry of expressed 
receptors with fluorescence tags and optimizing the ratio of  carrying baculovirus to be transfected 
into large scale HEK293 cultures, which were kept in the presence of nicotine [36]. In the resulting 
structure (Figure 1a), the receptor is likely to be in the desensitised state, as the TMD exhibits a 
clockwise twist, like the 3 GABAAR (also thought to be desensitised [10]). In both structures, the 
narrowest portion of the pore is at its intracellular end (-1’), a feature attributed to the desensitised 
state by functional studies [37**].   
In the 2- neuronal nAChR, two of the five possible orthosteric binding sites are at the 
4/2interface, where they are formed by the (+) side of 4 and the (-) side of 2 (Figure 1b). In the 
crystal, these sites are occupied by nicotine, which nestles in a cluster of aromatic side chains, the 
aromatic box typical of pLGICs [38]. One of the nicotine’s positive charges, the protonated pyrrolidine 
nitrogen, is close to the loop B Trp (TrpB, W156), and is in a good position to form a cation- interaction 
with the TrpB aromatic side chain and a hydrogen bond with the TrpB backbone carbonyl. This is an 
elegant confirmation of the results of 20 years of work by Dougherty, Lester and co-workers, who 
identified these two features by probing the binding site of pLGICs by unnatural amino acid 
mutagenesis. This technique makes it possible to weaken cation- interactions (by decreasing the 
electronegativity of aromatic rings with fluorine substituents) and to impair hydrogen bonds with the 
backbone (by decreasing the ability of backbone carbonyls to act as hydrogen bond acceptors; 
reviewed in [39]). The cation- interaction with TrpB was seen with all the nicotinic agonists tested in 
the functional studies, but was particularly important for nicotine. It is the strength of this interaction 
that makes nicotine much more potent on neuronal nicotinic receptors than on muscle receptors [40]. 
However, the new crystal structure does not immediately substantiate a third feature identified by 
functional studies: a proposed network of hydrogen bonds between the pyridine nitrogen of nicotine 
and the backbone of loop E via a water molecule. 
Perhaps the most striking feature of the 42 receptor structure is what happens in this heteromeric 
receptor at the remaining three binding sites at the ECD interfaces, i.e. the three interfaces where no 
ligand is bound. Here, the (+) side is contributed by 2 subunits and the (-) side by either a 2 subunit 
(2/2) or by the 4 subunit (2/4) (Figure 1c). The structure provides an elegant explanation for 
why none of these three sites are occupied by nicotine. On the principal side, loop B of the  subunit 
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contains a bulky Arg (R149), two residues before TrpB (the equivalent position in the  subunit is 
occupied by a Gly): the positively charged side chain of this Arg juts into the binding pocket, where it 
is stabilised by cation- interactions with the aromatic rings of TyrA (Y95) and TyrC2 (Y196). TyrC2 can 
rotate to take this position because the  subunit does not have a C1 aromatic amino acid. Another 
difference is that the side chain of TrpB of the  subunit (W151) is rotated out of the binding site 
(Figure 1c).    
 
Figure 1: Overview of the 42 nAChR structure and two of its orthosteric ligand-binding pockets. (a) 
Top-down view of the heteromeric 42 structure with 4 and 2 subunits shown in cyan and grey, 
respectively. The bound ligand nicotine is shown in pink. (b)/(c) Close up views of the 4 (+) / 2 (-) (b) 
and 2 (+) / 4 (-) (c) binding sites with the same colouring scheme as in (a). All panels based on PDB 
entry 5KXI. 
We have known for a while that agonist binding and channel activation are associated with (at least) 
two motions in the ECD: a quaternary twist of all the ECDs [41] and a closing or capping motion of loop 
C of the principal subunit [42]. In the / and / sites, loop C appears relatively open, but the distance 
between the two sides of the site (loops B and D) looks similar to that seen in the / sites that are 
occupied by a ligand. It may be that this distance is set by the symmetrical quaternary twist of the five 
ECDs. Both the / (and the /) sites are occupied by the loop B Arg149 and there is no room for a 
ligand molecule. It will be interesting to explore whether the cation- interaction formed by this Arg 
contributes to the stabilization of the open state, and therefore makes Arg act as an “endogenous 
agonist”, or whether Arg simply occupies the site, much like a competitive antagonist would. 
Indications that Arg occupancy of the / site may not be as efficacious as the binding of an agonist 
come from comparing the behaviour of the 2- and the 3- receptors. In particular, the channel 
maximum open probability is low for the 2- form and high (> 80%) for the 3- form [43-45].  It seems 
likely that this difference is caused by the binding of a third agonist molecule to the  site, and that 
 and  sites do not contribute to activation. Differences in how easily the two forms open (i.e. in 
the allosteric constant) cannot be excluded, as the TMD of the two forms is different. However, work 
with concatenated subunits [46] shows that switching one TMD from  to or vice versa has no effect 
on the sensitivity to ACh of the two types of channel. Conversely, the / interface has been confirmed 
to be non-functional, as mutating its aromatic box residues has essentially no effect on the 2-
receptor sensitivity to ACh.  
 neuronal nAChRs have been in the limelight recently also because of the discovery that poison 
frogs evolved resistance to the effects of the nicotinic agonist alkaloids they carry. Poison dart frogs 
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of tropical Central and South America acquire toxic alkaloids from their diet, and signal the presence 
of this chemical defence to predators by their distinctive bright colours. The alkaloids include the most 
potent of all  agonists, epibatidine. By sequencing the  and  genes in several genera, Tarvin 
and co-workers [47] identified a single Ser-to-Cys point mutation, which is present in all epibatidine-
carrying frogs. This residue (Cys108) is located in a  sheet between loop A and loop E of the 2 
subunit, in an area outside the binding site for ACh, which is much smaller than epibatidine.  
Introducing this mutation into the human 2 subunit makes the resulting  receptor almost 50-
fold less sensitive to epibatidine. However, it also reduces the ACh sensitivity of the receptor, but this 
is thought to be due to the increased presence of the low-sensitivity 3:2 stoichiometry (the ACh 
dose-response curve becomes biphasic). In contrast with these data from human receptors, 
intriguingly, frog receptors with this Cys residue have a normal sensitivity to ACh, and the authors 
show that this is due to the evolution of additional, compensatory sequence differences.  
2016 yielded another high-resolution view of a pLGIC binding site, that of glycine bound to the 
homomeric 3 GlyR in an X-ray crystal structure at 2.61 Å (the protein is bound also to the positive 
allosteric modulator AM-3607 and to zinc ions [48**]). This GlyR is also likely to be desensitised, given 
that the narrowest point of the pore is at its intracellular end [37**], at the Pro residue in -2’ (this 
residue is not present in cationic channels). The modulator binds in a novel binding site, at the top of 
the ECD interface, sharing loop B with the agonist orthosteric site just below it. The structure shows 
that glycine is lodged into the pocket with its amino group deep among the aromatic residues. Here, 
it is stabilised by a hydrogen bond with the backbone carbonyl of the loop B aromatic residue (PheB), 
by a cation- interaction with PheC2 and by a network of hydrogen bonds with loop B residues Glu157 
and Ser158, via a water molecule. The carboxyl moiety forms hydrogen bonds with the (+) subunit 
(Thr204 in loop C) and with the (-) subunit (Arg65 in loop D and Ser 129 in loop E). All of these 
interactions had been hypothesised from functional studies [49;50]. Further, unnatural amino acid 
mutagenesis [51] suggested PheB as the main aromatic forming a cation- interaction, but yielded less 
definitive results for PheC2. Note that particular caution is required in interpreting the effect of 
mutations in the GlyR binding pocket, because it is relatively small, and results may be confounded by 
steric clashes.  Two other structural features, the presence of a water molecule and the contact of 
glycine with loop B Ser 129 had been proposed by molecular dynamics work on a GluCl-based 
homology model (the role of loop B Ser was confirmed by functional mutagenesis [52]).   
Small molecule ligands and pLGIC function: outlook 
This is just the beginning. The latest high-resolution insights of the interactions between agonist and 
binding sites lay the foundation for many further questions. How do these interactions differ for 
agonists with different efficacy? How do these differences then spread to the ECD/TM interface and 
eventually to the pore? Does transduction need both the ECD quaternary twist and the capping of 
loop C? What is the basis of the increase in agonist affinity with activation? How exactly does the 
conformation of the binding site change as the channel moves from the resting state, to the first 
activation intermediates (identified by single channel biophysics and variously termed flip, primed, 
catch-and-hold [53-55]) to the open state and from the open to the desensitised state? Is there a 
progressive increase in agonist affinity? How are these processes influenced by endogenous 
modulators, such as neurosteroids (i.e. GABAAR-pregnanolone interaction; [56])?   
 
 6 
Beyond the agonist-binding pocket: discovery of new interaction partners, chaperones and accessory 
subunits 
It is becoming increasingly recognised that under physiological conditions, ion channels do not 
function in isolation, but interact with one or more partner proteins to form multi-component 
complexes [57]. Recent high-throughput screening, protein labelling and mass spectrometry (MS) data 
show that pLGICs are no exception. For pLGICs, several novel interacting proteins have been 
discovered in the last few years, not only offering a first glimpse into the fascinating functional 
consequences of these interactions, but also opening up new pharmacological avenues, distinct from 
those directly targeting the ion channel protein (Figure 2). 
 
Figure 2: Examples of recently identified protein-protein interactions involving pLGICs. An exemplary 
pLGIC is depicted in yellow in both the ER (lower panel) and the plasma membrane (upper panel). New 
proposed interactions involving GABAR-specific toxins (green) targeting the ECD, nAChr 7 and the ER 
resident protein NACHO (pink), putative GABAR auxiliary subunits from the GARLH family (blue) that 
form a tripartite complex with GABARs and neuroligin-2 (grey). Interactions of the scaffolding protein 
gephyrin (orange) and GlyRs/GABARs have been deciphered in great detail and recently targeted using 
synthetic peptides. 
The majority of pLGICs express readily in various cell lines to form functional receptors. The most 
striking exception is perhaps the homomeric 7 nAChR, which does not properly oligomerise and 
functionally express in most expression systems. The transmembrane protein RIC-3 (Resistance to 
Inhibitors of Cholinesterase-3) interacts with nAChRs and 5-HT3R subunits and promotes receptor 
maturation [58] (for a review see [59]), but even when co-expressed with RIC-3, 7 nAChRs express 
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poorly. Given their physiological importance [60], a recent study employed high throughput screening 
to pinpoint what proteins determine 7 nAChR expression, and screened nearly all human 
transmembrane and secreted proteins (a total of ca. 4000 clones [61**]). This identified a previously 
uncharacterised four-pass transmembrane protein, termed NACHO (novel nAChR regulator), which 
resides in the endoplasmic reticulum and promotes folding and surface expression of 7 nAChR and 
other nAChRs [62]. Using NACHO knockout mice, this neuronal protein was shown to be critical to 7 
nAChR assembly and function in the brain. NACHO is the first essential chaperone specific to a 
mammalian neurotransmitter receptor.  
Another notable advance has been in the field of accessory proteins. It has long been known that 
trafficking of several subtypes of nAChRs from the endoplasmic reticulum is enhanced by the human 
membrane-anchored proteins Lynx1 and 2 (lymphocyte antigen-6 protoxin), which also modulate 
nAChR gating [63-65]. However, no bona fide auxiliary subunits were known for pLGICs until the recent 
discovery of the GARLH (GABAA Regulatory Lhfpl)-type transmembrane proteins. GARLHs control 
GABAAR synaptic localisation and GABA-mediated synaptic transmission by anchoring 2-containing 
GABAARs to synaptic neuroligin-2 (NL-2), another synaptic transmembrane protein [66]. Specifically, 
the authors propose that GARLH4 forms a trimeric complex with (2-containing) GABAARs and NL-2. 
Evidence of a direct GARLH4/GABAAR interaction is still missing and we do not know if the formation 
of this complex has functional consequences (the proposed auxiliary subunit does not appear to affect 
the action of agonists or antagonists). Another recent report suggests that GARLHs may determine 
some of the (notoriously complex) assembly rules for GABAARs [67]. A key question for the future is 
exactly how and when the proposed trimeric LN-2/GARLH4/GABAAR complex interacts with the 
intracellular scaffold protein gephyrin. While gephyrin is already the best characterised of all 
intracellular partners of pLGICs, such as GABAARs and GlyRs [68], new studies have recently offered 
insight into the nature of the gephyrin/receptor interactions at atomic and cellular levels [69;70]. 
These advances were enabled by the development of peptides that disrupt the gephyrin/receptor 
interaction with high affinity and specificity [71**]. These tools allowed Maric and co-workers [69] to 
show that GlyR-mediated inhibitory synaptic transmission is impaired by the loss of the interaction 
between the receptor and the intracellular scaffold (and by the resulting loss of receptor accumulation 
at the synapse). Another recent report showed that the small molecule antimalarial drug artemisinin 
can stabilize gephyrin to enhance GABAAR signalling and thereby promote conversion of pancreatic  
cells into functional  cells [72]. Together, this opens up a novel route for pharmacological targeting 
of pLGICs and other ion channels by using peptides to disrupt physiologically relevant protein-protein 
interactions (see also [73] for a recent review). This route has considerable potential for enabling 
greater receptor specificity, given that they target cytoplasmic loops, which are much less conserved 
across different pLGIC subunits and subtypes than orthosteric ECD binding sites. 
In general, peptide-derived drugs are able to recognise and bind biological targets with greater 
specificity than small molecule drugs/ligands. In many cases, nature provides useful blueprints for 
such drug candidates in the form of peptide toxins that are already highly evolved to develop high 
affinity and specificity to their protein target. However, examples among pLGICs have remained 
scarce, with the exception of the reasonably well-characterised interactions of the orthosteric binding 
site of nAChRs with -bungarotoxin and conotoxins [74]. A recent breakthrough came from the 
discovery of the first GABAR-specific toxins from coral snake venom [75], which potently modulate 
GABAAR activity. Although these particular peptides will likely serve mostly as tool compounds to 
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decipher GABAergic synaptic transmission, they could serve as a starting point to target the dazzling 
variety of GABAARs with more specific therapeutics in the future. The development of new 
computational approaches for toxin docking and virtual screening using pLGIC structures or models as 
templates is therefore a highly timely development [76]. 
Protein-protein interactions in pLGICs: outlook 
These examples highlight the discoveries of numerous new interaction partners of pLGICs in recent 
years. With evermore-elaborate proteomic and MS tools to discover novel synaptic interactions 
[77**;78], there is no doubt that the pace of discovery in this field will continue to accelerate. Such 
efforts are highly timely, as the identification of pLGIC protein-protein interactions is still in its infancy, 
and most examples of interactions with chaperones, auxiliary subunits and scaffold proteins are at 
present limited to a single receptor subtype or subunit (Figure 2). The key question is whether all pLGIC 
subtypes will turn out to have a similar complement of interacting proteins, especially in the light of 
the low sequence conservation of their intracellular loops. Research into protein-protein interactions 
will be complemented by the recent surge in cryo-EM structures of ion channel complexes, which (in 
contrast to most X-ray structures) will hopefully provide much-needed structural information on 
intracellular loops. This will help clarify the structural basis of protein-protein interactions, further 
facilitating and complementing their functional elucidation. This is particularly important, as our 
knowledge of these interactions lags far behind the level of detail known for the interactions occurring 
in and around the agonist-binding pocket. 
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